BioSpace News Archive

China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced that the masks produced by its subsidiary Hainan Helpson Medicine & Biotechniqe Co., Ltd. has rece

DarioHealth Corp. (Nasdaq: DRIO), today announced that the companies have entered into a sales and distribution partnership pursuant to which HMC will incorporate DarioHealth’s digital therapeutics solution

First-Line Treatment With Merck’s KEYTRUDA ® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TPS > 50%) Results From KEYNOTE-024 Represent Longest Follow-Up of an Immunotherapy in a Randomized Phase 3 Study for the First-Line Treatment of Lung Cancer Duration of Response With KEYTRUDA As Monotherapy (29.1 Months) Was Nearl

Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59 ® adjuvanted, trivalent influenza vaccine (aTIV) was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and h

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into an evaluation agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the potential use of the company’s high concentration delivery technology

Voycare, Inc. is pleased to announce it has signed a formal Memorandum of Understanding with CITCON, a global cross-border mobile payment and commerce solution provider, trusted by over 10,000 leading brands including MGM Resorts, Bloomingdales, Dior, Tumi, Panda Express, and others.

Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24. Dr. Countouriotis is scheduled to discuss the company in a “fireside chat” format at 10:30 a.m. ET and

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that positive results from the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project comparing TCAR and carotid endarterectomy (CEA) have been published in Annals of Surgery1.

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples Solution Receives AOAC ® PTM SM Certification